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l Figure 3 shows the yearly treatment cost of patients over the time period. The total costs add up to € 36'874'827 in 2015 and the total treatment cost grew yearly on average by 11.3% from 2012 to 2015.
The total number of patients grew yearly on average by 9.7% from 2012-2015. As expected, the key cost driver were biological agents which account for 90.5% of total cost (in 2015) . The costs could be slightly overestimated due to potential intersections of patients who begin, repeat or switch the therapy. With regard to 2016, comprehensive data sets only exist for Q1/2016 and Q2/2016, data from Q3/2016 is incomplete. This has to be taken into account when interpreting the data. l The study demonstrated that the leading biological agents for 1st line treatment are adalimumab and apremilast at a low level of share of prescriptions (Q2/2016: 1,84% and 1,55% respectively). 
CONCLUSIONS:
l Adalimumab, apremilast and etanercept are those biological agents mainly used for treating PsO.
l Costs grew steadily over the last four years with biological agents being the key cost driver.
l Total costs in 2015 were € 36.9 million and on average € 18'067 per patient.
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GERMAN SITUATION OF TREATMENT WITH BIOLOGICAL AGENTS AMONG PATIENTS WITH PSORIASIS BASED ON A CLAIMS DATA ANALYSIS

BACKGROUND:
l Psoriasis (PsO) is not curable; however, for many people treatment will help to control the disease [1] .
l This study provides information on the current supply with biological agents and its related costs (other medication, outpatient care, hospital admission) in Germany.
METHODS:
l The design is a retrospective claims data analysis. l The study evaluated direct medical costs (drugs, outpatient care and hospital admission), hospital admission and change in medication.
l Treatment costs included costs for biological agents which were approved for the treatment of PsO (as of April 2017, see also Table  2 ). Furthermore, the following medication groups were considered to be PsO related (see also l In case that a patient changed therapy during the observation period, he was further included only if he continued receiving a biological agent.
l Figure 1 depicts an overview of the analysis of the sample. 
RESULTS:
l Most patients with PsO are aged above 46, thereby the proportion below 17 years' account for less than 1%. The average age of all age cohorts is 49.6 years, with the subgroup of men slightly younger than women (48.6 yr men vs. 50.9 yr women).
• The proportion of men is slightly higher than that of women (54.5% male vs 45.5% female) (see also Figure 2 ). 
